

October 11, 2022

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) – Appointment of Compliance Officer.

Dear Sir/Madam,

With reference to the above-mentioned subject and pursuant to Regulation 30 of SEBI LODR, we are pleased to inform that the Board of Directors of the Company vide Circular Resolution passed today i.e. October 11, 2022 has approved the appointment of Mr. Udayan Shukla, a Qualified Company Secretary from the Institute of Company Secretaries of India, as the Compliance officer of the Company.

The Brief Profile of Mr. Udayan Shukla as per SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed as **Annexure – A**.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

ASHISH
MAHESHWARI

Digitally signed by
ASHISH MAHESHWARI
Date: 2022.10.11
16:43:58 +05'30'

Ashish Maheshwari
(Managing Director)
(DIN: 01575984)

Enclosure: As above.

Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

(Formerly known as Balaxi Ventures Limited)

